WHO Granted Prequalification to Cervavac HPV Vaccine
The international health agency has approved the Serum Institute of India vaccine for global distribution.
Updated on Oct. 5, 2026 in Cancer
Live Poll
Should international health agencies prioritize the certification of vaccines developed in emerging economies?
The World Health Organization has officially granted prequalification status to the Cervavac HPV vaccine. This move now allows United Nations agencies to procure and distribute the vaccine on a global scale.
Why it matters
Prequalification is a critical step that ensures the vaccine meets international standards for quality, safety, and efficacy. By clearing the vaccine for global use, the WHO aims to broaden access to prevention for cervical, vulvar, vaginal, and anal cancers.
The Cervavac vaccine targets HPV types 6, 11, 16, and 18 for individuals aged 9 through 26 years. Clinical administration consists of a 0.5 mL dose, available in both 1-dose and 2-dose vial presentations.
The players
World Health Organization
The United Nations agency responsible for international public health and setting global medical standards.
Serum Institute of India
A major global vaccine manufacturer based in India that develops and produces various immunization products.
The details
Developed by the Serum Institute of India, the vaccine also prevents genital warts caused by HPV types 6 and 11. Patients aged 9 to 14 require two doses at 0 and 6 months, while those aged 15 to 26 must receive three doses at 0, 2, and 6 months via intramuscular injection.
Timeline
October 5, 2026: The WHO granted prequalification status to the Cervavac vaccine.
Health Landscape
This approval marks a significant milestone for the WHO Prequalification Programme as it adds a new tool to international immunization efforts. The inclusion of Cervavac expands the available options for global cancer prevention strategies previously reliant on a limited number of suppliers.
This development increases the availability of HPV vaccination for individuals aged 9 to 26 years across various nations. Patients should consult their local health providers to determine when this vaccine becomes accessible within their specific healthcare system.
The takeaway
Universal access to HPV vaccines is a vital pillar in the long-term reduction of virus-related cancers. Individuals are encouraged to speak with medical professionals about the recommended dosing schedules for their age group.
Further reading
Learn more about the latest developments in cancer prevention on the Cancer page.
Live Poll
Should international health agencies prioritize the certification of vaccines developed in emerging economies?
